Semaglutide, sold under the brand names Wegovy, Ozempic and Rybelsus, has become a popular choice of GLP-1 receptor agonists among patients
Findings: RCTSemaglutide vs Placebo for Alcohol Use Disorder in Adults, JAMA Psychiatry (2025) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=48 | length = 9 weeks) in non-treatment-seeking adults with alcohol use disorder Treatment: Semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week) vs Placebo Primary outcome: Objective alcohol self-administration (at baseline and between Weeks 8 and 9) measured as follows: a standardized procedure was used to estimate voluntary alcohol consumption and ability to delay drinking
00:08:41 Vickie Danaher When patients do get oral semaglutide for obesity, keep in mind that it has similar GI side effects as injectable semaglutide, so things like nausea and upset stomach, and help ensure proper dose titration to help limit these effects
Getting Started Not yet a subscriber
As our understanding of obesity evolves, so does the conversation around healthy aging and the long-term benefits of metabolic interventions
It is always best to have a licensed healthcare provider confirm this before you attempt an injection
